A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Inclusion Criteria:

• Participant has a diagnosis of CM with or without aura according to theInternational Classification of Headache Disorders Edition 3 criteria for ≥ 12months and is able to distinguish migraine headaches from all other types ofheadaches;

• Participant age < 50 years at the time of migraine onset;

• Participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of ≥ 15 headache days per month and history of ≥ 8 migraine days per month; and

• During the last 28 days of the screening period, participant experiencing: ≥ 15headache days and ≥ 8 migraine days that qualify as such per the headache diary.

Exclusion Criteria:

• Diagnosis of other primary headache types, except tension-type headache, which ispermitted;

• Diagnosis of aura without headache, migraine with brainstem aura, hemicraniacontinua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aurawithout infarction, migraine aura-triggered seizure, or previous migrainousinfarction;

• Diagnosis of secondary headache types, except medication overuse headache, which ispermitted;

• Currently taking > 1 prescribed drug for the preventive treatment of migraine;

• Discontinuation of anti-calcitonin gene-related peptide (CGRP) / anti-CGRP receptormonoclonal antibody treatment less than 5 months prior to screening.